Ganglioside containing nano-proteoliposome dampens myeloid-derived suppressor cells function and ability to cross-present tumor antigens: a new approach to recover CTL function on tumor bearing individuals

Fernández, Audry; Oliver, Liliana; Rábade-Chediak, Maura; Alvarez, Rydell; Hernández, Arletty; Pérez, Leslie; Fernández, Luis E.; Mesa, Circe

doi:10.1186/2051-1426-1-s1-p225

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VSSP were proved to modulate the suppressive activity of tumor-derived MDSCs in mice by inducing their differentiation to APCs (Fernández et al 2011(Fernández et al , 2013, and on the basis of these results, the development of a vaccine able to target these immunosuppressive cells whilst eliciting an immune response towards the associated antigen has been proposed.…”

Section: Nanocarriers Targeted To Mdscsmentioning

confidence: 99%

Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation

2014

View full text Add to dashboard Cite

Section: Nanocarriers Targeted To Mdscsmentioning

confidence: 99%

Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation

2014

View full text Add to dashboard Cite

“…Nevertheless, these splenic myeloid cells did not exert any relevant immunosuppression on T cells. In addition, the injection of this adjuvant in tumour-bearing mice was able to modulate the phenotype of splenic MDSC towards APCs and strongly reduce their ability to impair cytotoxic T cell activation (182,186). A similar example was provided by Thomas et al, who showed that poloxamer-stabilized poly (propylene sulfide) nanoparticles (30 nm), loaded with either CpG or paclitaxel, were able to specifically target tumour-draining lymph nodes and reduce MDSC activity (187) ( Table 3).…”

Section: Therapeutic Interventions On Mdscmentioning

confidence: 99%

Nanomedicine and cancer immunotherapy – targeting immunosuppressive cells

Andón

Alonso

2015

Journal of Drug Targeting

View full text Add to dashboard Cite

The search for pharmacological strategies to reach and impact on immunosuppressive cells is, currently, one of the most exciting areas in cancer immunology and clinical oncology. In this context, it is increasingly accepted that the success of these therapies will largely depend on the availability of appropriate drug delivery strategies. Considering the critical role that nanotechnology plays in the development of these novel therapies, the main goal of this article is to provide an overview of the potential of nanomedicines targeted to immunosuppressive cells for the treatment of cancer. We present, first, a brief description of classical cancer immunotherapies based on therapeutic vaccination and monoclonal antibodies, with a special focus on the use of nanotechnologies and the targeting of immunological checkpoints. Second, we provide a thoughtful analysis of the possibilities to target the immunosuppressive cells, namely tumour-associated macrophages, myeloid-derived suppressor cells, tumour-associated neutrophils and regulatory T cells, at the tissue level (i.e. tumour, spleen, blood, lymph) and, also, at the cellular level. Finally, we wrap the article with a disclosure of strategies used to impair the generation, kill or re-educate these immunosuppressive cells, thus providing an up-to-date picture of the choices available for therapeutic intervention.

show abstract

“…Nanomedicine combined with immunotherapy aimed at inhibiting immune cell activation or recruitment via an appropriate drug delivery platform might represent a potent intervention approach to fight diseases [ 20 , 21 ]. For instance, nanoproteoliposomes were deployed as nanocarriers for the antigen GM3 ganglioside in renal carcinoma-bearing mice, demonstrating that these nanoproteoliposomes could significantly transform the splenic DC phenotype towards APCs, followed by inhibition of the immune-suppressive characteristics of splenic DCs to promote subsequent cytotoxic T-cell activation [ 22 , 23 ]. Moreover, polymeric nanoparticles loaded with CpG or paclitaxel were found to effectively target DCs within lymph nodes, which drastically reduced DC immune activity [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Immune-regulating strategy against rheumatoid arthritis by inducing tolerogenic dendritic cells with modified zinc peroxide nanoparticles

et al. 2022

View full text Add to dashboard Cite

In hypoxic dendritic cells (DCs), a low level of Zn2+ can induce the activation of immunogenic DCs (igDCs), thereby triggering an active T-cell response to propel the immune progression of rheumatoid arthritis (RA). This finding indicates the crucial roles of zinc and oxygen homeostasis in DCs during the pathogenesis of RA. However, very few studies have focused on the modulation of zinc and oxygen homeostasis in DCs during RA treatment. Proposed herein is a DC-targeting immune-regulating strategy to induce igDCs into tolerogenic DCs (tDCs) and inhibit subsequent T-cell activation, referred to as ZnO2/Catalase@liposome-Mannose nanoparticles (ZnCM NPs). ZnCM NPs displayed targeted intracellular delivery of Zn2+ and O2 towards igDCs in a pH-responsive manner. After inactivating OTUB1 deubiquitination, the ZnCM NPs promoted CCL5 degradation via NF-κB signalling, thereby inducing the igDC-tDC transition to further inhibit CD4+ T-cell homeostasis. In collagen-induced arthritis (CIA) mice, this nanoimmunoplatform showed significant accumulation in the spleen, where immature DCs (imDCs) differentiated into igDCs. Splenic tDCs were induced to alleviate ankle swelling, improve walking posture and safely inhibit ankle/spleen inflammation. Our work pioneers the combination of DC-targeting nanoplatforms with RA treatments and highlights the significance of zinc and oxygen homeostasis for the immunoregulation of RA by inducing tDCs with modified ZnO2 NPs, which provides novel insight into ion homeostasis regulation for the treatment of immune diseases with a larger variety of distinct metal or nonmetal ions. Graphical Abstract

show abstract

Ganglioside containing nano-proteoliposome dampens myeloid-derived suppressor cells function and ability to cross-present tumor antigens: a new approach to recover CTL function on tumor bearing individuals

Abstract: Cite this article as: Fernández et al.: Ganglioside containing nanoproteoliposome dampens myeloid-derived suppressor cells function and ability to cross-present tumor antigens: a new approach to recover CTL function on tumor bearing individuals.

Cited by 4 publications

References 0 publications

Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation

Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation

Nanomedicine and cancer immunotherapy – targeting immunosuppressive cells

Immune-regulating strategy against rheumatoid arthritis by inducing tolerogenic dendritic cells with modified zinc peroxide nanoparticles

Contact Info

Product

Resources

About